Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
10/2003
10/09/2003WO2003082280A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
10/09/2003WO2003082277A1 Thiazol-2-yl-imine compounds as pde-7 inhibitors
10/09/2003WO2003082275A1 Treatment of dependence and dependence related withdrawal symptoms
10/09/2003WO2003082270A1 Method for treating cognitive disorders
10/09/2003WO2003082269A1 Use of statins and other immunomodulatory agents in the treatment of autoimmune disease
10/09/2003WO2003082262A2 Compositions of venlafaxine base
10/09/2003WO2003082261A1 Extended release venlafaxine formulations
10/09/2003WO2003082259A1 Natural phenolic products and derivatives thereof for protection against neurodegenerative diseases
10/09/2003WO2003082255A2 Use of mob-5 in pain
10/09/2003WO2003082216A2 Neuroprotectant methods, compositions, and screening methods thereof
10/09/2003WO2003082198A2 Methods of treatment with lxr modulators
10/09/2003WO2003082197A2 Immunosuppressant compounds, methods and uses related thereto
10/09/2003WO2003082196A2 Combination therapy using trefoil peptides
10/09/2003WO2003082191A2 Substituted 2,3-diphenyl pyridines
10/09/2003WO2003082190A2 Spirocyclic amides as cannabinoid receptor modulators
10/09/2003WO2003059376A8 The use of il6r/il6 chimera in nerve cell regeneration
10/09/2003WO2003045328A3 Methods of making and using theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate and theaflavin 3,3'-digallate and mixtures thereof
10/09/2003WO2003030927A3 Use of thymulin-like peptides for making pain-relieving medicines
10/09/2003WO2003029828A3 Screening method for different indications using bnpi and/or dnpi
10/09/2003WO2003026621A3 Method for making an oral pharmaceutical product with tell-tale agents, in particular of taste and resulting product
10/09/2003WO2003016341A3 Regulation of iron uptake
10/09/2003WO2003013534A3 Methods for the treatment of cancer with irinotecan based on cyp3a5
10/09/2003WO2003013533A3 Methods for improved treatment of cancer with irinotecan based on mrp1
10/09/2003WO2003006893A3 Methods of inhibiting amyloid toxicity
10/09/2003WO2002092004A3 Use of hmg fragment as anti-inflammatory agents
10/09/2003WO2002083627A3 Ligands des integrins avss6
10/09/2003WO2002078747A3 Pregabalin lactose conjugates
10/09/2003WO2002078682A3 Estrogen replacement therapy
10/09/2003WO2002077017A3 Medical uses of intercellular communication facilitating compounds
10/09/2003WO2002074056A3 Allosteric adenosine receptor modulators
10/09/2003WO2002069905A3 Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
10/09/2003WO2002057484A3 Method and test system for identifying substances which protect nerve cells
10/09/2003WO2002056905A3 Molecular antigen array
10/09/2003WO2002055063A3 Fumaric acid amides
10/09/2003WO2002053743A3 Mammalian tribbles signaling pathways and methods and reagents related thereto
10/09/2003WO2002033099A3 Human kinases
10/09/2003WO2002032449A3 Method for treating ischemic events affecting the central nervous system
10/09/2003WO2002026245A3 Use of serp-1 in combination with an immunosuppressant for influencing inflammatory and immune reactions
10/09/2003WO2002017953A3 Thrombomodulin analogs for use in recovery of signal cord injury
10/09/2003WO2002016434A9 T CELL RECEPTOR Vβ-Dβ-Jβ SEQUENCE AND METHODS FOR ITS DETECTION
10/09/2003WO2002009686A3 Cdc25 phosphatase inhibitors
10/09/2003US20030191347 Venlafaxine base
10/09/2003US20030191315 A chemical intermediate reaction by starting 2,6-diaminopyridine with malic acid and sulfuric acid, salt formation, hydroxylation, chlorination, dehydroxylation, reduction, esterification
10/09/2003US20030191311 Imidazole derivatives
10/09/2003US20030191285 Novel g protein-coupled receptor proteins and dnas thereof
10/09/2003US20030191188 Method for treating migraine symptoms with ibuprofen and salts thereof
10/09/2003US20030191187 Aqueous solution containing phosphate; adjustment pH
10/09/2003US20030191181 4-[(8-Ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-benzoic and 2-[4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-phenyl]-acetic acid, their esters and salts having cytochrome P450RAI inhibitory activity
10/09/2003US20030191180 Pharmaceutical compositions
10/09/2003US20030191177 Maintenance dosage of beta blocker; cardiovascular disorders
10/09/2003US20030191174 Novel bicyclic compounds
10/09/2003US20030191172 Method of using cyclooxygenase inhibitors and antimuscarinic agents
10/09/2003US20030191167 Autoimmune disease, antiarthritic agents, antiallergens, anticancer agents
10/09/2003US20030191155 Triazole derivatives
10/09/2003US20030191136 Melanin concentrating hormone receptor ligands
10/09/2003US20030191135 Serotonergic agents with long-acting in vivo effects
10/09/2003US20030191133 Indole derivatives useful for the treatment of CNS disorders
10/09/2003US20030191130 [1,2,4]-Triazole bicyclic adenosine A2a receptor antagonists
10/09/2003US20030191126 Psychological disorders; antidepressants
10/09/2003US20030191125 Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof
10/09/2003US20030191124 Derivatives of sulphonamides, their preparation and use as medicaments
10/09/2003US20030191122 Antidepressants; Alzheimer's disease; Parkinson's disease; central nervous system disorders
10/09/2003US20030191120 Antiparkinsonism drugs
10/09/2003US20030191117 Acyclic piperazine and piperidine derivatives
10/09/2003US20030191114 Binding to ligand; induce signals
10/09/2003US20030191110 Anticholesterol agents; cardiovascular disorders
10/09/2003US20030191104 Therapy for carbohydrate metabolism disorders
10/09/2003US20030191103 Hormone replacement therapy
10/09/2003US20030191097 Hormone replacement therapy
10/09/2003US20030191092 MMP inhibitors
10/09/2003US20030191086 Substituted nitrogen heterocyclic derivatives and pharmaceutical use thereof
10/09/2003US20030191065 Insulin-like growth factor; genetic engineering; central nervous system disorders
10/09/2003US20030191057 Cardiovascular disorders; antiinflammatory agents
10/09/2003US20030190709 Modulation apoptosis; Alzheimer's diseases; Parkinson's disease; amyotropic lateral sclerosis
10/09/2003US20030190707 17 human secreted proteins
10/09/2003US20030190687 Interacts with human DR5 to produce agonistic or antagonistic effects including inhibition of cell proliferation and apoptosis; used to treat apoptosis-related disease and unregulated cell growth
10/09/2003US20030190685 Bind to Tumor Necrosis Factor(TNF)-Related Apoptosis Inducing Ligand (TRAIL) receptors ; used in the prevention and treatment of cancers and other proliferative disorders
10/09/2003US20030190651 Preventing, ameliorating, correcting dysfunctions or diseases such as cancer, peripheral and central nervous system diseases, and chronic obstructive pulmonary disease
10/09/2003US20030190642 Thymus expressed human cytochrome p450(p450tec)
10/09/2003US20030190635 RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
10/09/2003US20030190613 Polynucleotide encoding an activated human T-lymphocyte-derived protein related to ubiquitin conjugating enzyme
10/09/2003US20030190375 Therapeutical use of sophora flavescens or sophora subprostrata extracts
10/09/2003US20030190368 Identification of cellular activation factors and their use as diagnostic markers
10/09/2003US20030190363 Infant formulas containing long-chain polyunsaturated fatty acids and uses thereof
10/09/2003US20030190352 Compositions of venlafaxine base
10/09/2003US20030190351 Venlafaxine hydrochloride and sodium carboxymethyl cellulose; antidepressant
10/09/2003US20030190290 And dispensing devices for improved administration of opiod analgesics such as fentanyl, alfentanil, carfentanil, remifentanil, sufentanil, buprenorphine, morphine, diamorphine
10/09/2003CA2481253A1 Vegf peptides and their use
10/09/2003CA2480888A1 New aryl imidazoles and related compounds as c5a receptor modulators
10/09/2003CA2480869A1 Anxiolytic agents with reduced sedative and ataxic effects
10/09/2003CA2480857A1 Improvements in pharmaceutical compositions
10/09/2003CA2480695A1 Polycyclic compounds as potent alpha2-adrenoceptor antagonists
10/09/2003CA2480686A1 Piperazinyl- or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase
10/09/2003CA2480679A1 (4,2-disubstituted-thiazol-5-yl)amine compounds as pde7 inhibitors
10/09/2003CA2480634A1 Use of statins and other immunomodulatory agents in the treatment of autoimmune disease
10/09/2003CA2480633A1 Neurotrophic and neuroprotective peptides
10/09/2003CA2480568A1 Thiazol-2-yl-imine compounds as pde-7 inhibitors
10/09/2003CA2480436A1 Composition comprising an extract of liriopsis tuber for protecting brain cells and improving memory
10/09/2003CA2480372A1 Combination therapy using trefoil peptides
10/09/2003CA2480317A1 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders
1 ... 1162 1163 1164 1165 1166 1167 1168 1169 1170 1171 1172 1173 1174 1175 1176 1177 1178 1179 1180 1181 1182 ... 1833